Sugi Predict

Sugi Predict / Compounds / SCHEMBL4296569

SCHEMBL4296569

SCHEMBL4296569

CC(C)(C)OC(=O)Nc1ccc2cnccc2n1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 2/20 0.47
▸ NAMPT P43490 2/20 0.44
▸ CYP17A1 P05093 3/20 0.43
▸ GSK3B P49841 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41
▸ RAB9A P51151 1/20 0.40
▸ LATS1 O95835 5/20 0.40
▸ LATS2 Q9NRM7 1/20 0.39
▸ UGCG Q16739 1/20 0.39
▸ ATR Q13535 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MALT1 Q9UDY8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6640114 0.84 CYP3A4 (0.47) ROCK2NAMPTRAB9ALATS1LATS2
SCHEMBL21070179 0.77 ROCK2 (0.58) ROCK2RAB9AUGCGMALT1
SCHEMBL30381667 0.77 DYRK1A (0.54) NAMPTCYP17A1GSK3BDYRK1ARAB9A
SCHEMBL12567166 0.77 SORT1 (0.43) GSK3BDYRK1ARAB9A
SCHEMBL4300693 0.76 LIMK1 (0.41) NAMPTCYP17A1LATS1
SCHEMBL30908325 0.76 NPC1 (0.45) GSK3BDYRK1ARAB9AMAPT
SCHEMBL23535706 0.76 TDP1 (0.43) GSK3BDYRK1ARAB9AMAPT
SCHEMBL4580110 0.76 GSK3B (0.40) NAMPTCYP17A1GSK3BDYRK1ARAB9A
SCHEMBL31504571 0.76 TDP1 (0.43) GSK3BDYRK1ARAB9AMAPT
SCHEMBL29852425 0.75 CTSA (0.40) RAB9ALATS1LATS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 — — EP disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 — — US disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 — — US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 — — US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 — — US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 — — US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 — — US disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 — — US disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ROCK2 2938/4885NAMPT 1694/4885CYP17A1 1927/4885
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ROCK2 2938/4885NAMPT 1694/4885CYP17A1 1927/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ROCK2 2938/4885NAMPT 1694/4885CYP17A1 1927/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ROCK2 2938/4885NAMPT 1694/4885CYP17A1 1927/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ROCK2 2938/4885NAMPT 1694/4885CYP17A1 1927/4885
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 ROCK2 653/4885NAMPT 725/4885CYP17A1 1311/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 ROCK2 615/4885NAMPT 793/4885CYP17A1 1191/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ROCK2 2938/4885NAMPT 1694/4885CYP17A1 1927/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ROCK2 2938/4885NAMPT 1694/4885CYP17A1 1927/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ROCK2 2938/4885NAMPT 1694/4885CYP17A1 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.